Interestingly, TCDD exclusively modulated a cluster of 13 genes (i.e., not found in any other treatment) into the same direction as in the HCC signature, including membrane trafficking regulators (OPTN), nuclear-cytoplasmic transporters (MVP) and genes encoding structural proteins (COMP, TNNI2 and MAPT). This evidence concerns the gene MVP and hepatocellular carcinoma.